ArticleBMC biotechnology2025
Optimization of in vivo delivery methods and their applications in seminiferous tubules of mice.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore and optimize the conditions for in vivo transfection and gene editing, emphasizing their potential applications in the treatment of infertility in mice. Our findings indicate that physical transfection can be effective in the dynamic fluid environment of mouse seminiferous tubules, with electroporation achieving transfection in multilayered cell tissues. Using the mTmG fluorescence reporter system, we visually assessed the efficiency of electroporation-based transfection and observed stable gene editing outcomes across different individuals. Additionally, we achieved effective transfection of germ cells in vivo for the clinical application of gene tools. We further investigated the impact of various delivery methods and molecular methods on transfection efficacy, revealing that RNP technology is adaptable and efficient in vivo, particularly in the context of treating hereditary diseases. We attempted to leverage gene editing techniques to address spermatogenesis blockage at different stages in Ythdc2-KO and CK137956-KO mice. While we did not succeed in rescuing spermatogenic blockage in Ythdc2 KO mice, the treatment of CK137956 KO mice yielded significant physiological responses. These results could be beneficial for the optimization of in vivo gene editing technologies for clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.